Prospective multicentre study on azole resistance in Aspergillus isolates from surveillance cultures in haematological patients in Italy.


Journal

Journal of global antimicrobial resistance
ISSN: 2213-7173
Titre abrégé: J Glob Antimicrob Resist
Pays: Netherlands
ID NLM: 101622459

Informations de publication

Date de publication:
09 2020
Historique:
received: 11 12 2019
revised: 16 01 2020
accepted: 25 01 2020
pubmed: 18 2 2020
medline: 24 6 2021
entrez: 17 2 2020
Statut: ppublish

Résumé

This study was conducted to assess the prevalence of azole resistance in Aspergillus isolates from patients with haematological malignancies or who were undergoing haematopoietic stem cell transplantation and to identify the molecular mechanism of resistance. In this 28-month prospective study involving 18 Italian centres, Aspergillus isolates from surveillance cultures were collected and screened for azole resistance, and mutations in the cyp51A gene were identified. Resistant isolates were genotyped by microsatellite analysis, and the allelic profiles were compared with those of resistant environmental and clinical isolates from the same geographical area that had been previously genotyped. There were 292 Aspergillus isolates collected from 228 patients. The isolates belonged mainly to the section Fumigati (45.9%), Nigri (20.9%), Flavi (16.8%) and Terrei (4.8%). Three isolates showed itraconazole resistance: Aspergillus fumigatus sensu stricto, Aspergillus lentulus (section Fumigati) and Aspergillus awamori (section Nigri). The itraconazole resistance rates were 1% and 1.48% considering all Aspergillus spp. isolates and the Aspergillus section Fumigati, respectively. The prevalence of azole resistance among all the patients was 1.3%. Among patients harbouring A. fumigatus sensu stricto isolates, the resistance rate was 0.79%. The A. fumigatus isolate, with the TR In this study, the Aspergillus azole resistance rate was 1% (3/292). In addition to A. fumigatus sensu stricto, A. lentulus and A. awamori azole-resistant isolates were identified. Therefore, it is important have a correct identification at the species level to address a rapid therapy better, quickly understand the shift towards cryptic species and have an updated knowledge of the local epidemiology.

Identifiants

pubmed: 32061880
pii: S2213-7165(20)30017-5
doi: 10.1016/j.jgar.2020.01.016
pii:
doi:

Substances chimiques

Antifungal Agents 0
Azoles 0

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

231-237

Informations de copyright

Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Auteurs

A Prigitano (A)

Department of Biomedical Sciences for Health, Università degli Studi di Milano, Milan, Italy. Electronic address: anna.prigitano@unimi.it.

M C Esposto (MC)

Department of Biomedical Sciences for Health, Università degli Studi di Milano, Milan, Italy.

A Grancini (A)

I.R.C.C.S. Foundation, Cà Granda Ospedale Maggiore Policlinico, Milan, Italy.

M Passera (M)

Microbiology and Virology Unit, Asst. Papa Giovanni XXIII, Bergamo, Italy.

M Paolucci (M)

Institute of Hematology, Lorenzo e Ariosto Seràgnoli, Sant'Orsola-Malpighi Hospital Policlinico, University of Bologna, Bologna, Italy.

M Stanzani (M)

Institute of Hematology, Lorenzo e Ariosto Seràgnoli, Sant'Orsola-Malpighi Hospital Policlinico, University of Bologna, Bologna, Italy.

A Sartor (A)

Division of Hematology, ASUIUD, University of Udine, Udine, Italy.

A Candoni (A)

Division of Hematology, ASUIUD, University of Udine, Udine, Italy.

L Pitzurra (L)

Dipartimento di Medicina, Università degli Studi di Perugia, Perugia, Italy.

P Innocenti (P)

Laboratory of Microbiology and Virology, Comprensorio Sanitario di Bolzano-AS Alto Adige, Bolzano, Italy.

A Micozzi (A)

Department of Translational and Precision Medicine, Sapienza Università di Roma, Rome, Italy.

G Lo Cascio (GL)

Microbiology Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.

M Delia (M)

Department of Emergency and Organ Transplantation-UO Haematology with transplantation, AO Universitaria Policlinico di Bari, Bari, Italy.

A Mosca (A)

Interdisciplinary Department of Medicine, AO Universitaria Policlinico di Bari, Bari, Italy.

M Mikulska (M)

Università degli Studi di Genova (DISSAL) and Ospedale Policlinico San Martino, Genoa, Italy.

C Ossi (C)

Laboratory of Microbiology and Virology, San Raffaele Scientific Institute, Milan, Italy.

C Fontana (C)

Department of Experimental Medicine, University of Tor Vergata Polyclinic of Tor Vergata, Rome, Italy.

M Pizzolante (M)

Laboratory of Microbiology, Vito Fazzi Regional Hospital Lecce, Lecce, Italy.

M Gelmi (M)

ASST Spedali Civili di Brescia, Brescia, Italy.

C Cavanna (C)

Microbiology and Virology Unit, IRCCS Policlinico San Matteo, Pavia, Italy.

F Lallitto (F)

Microbiology and Virology Unit, IRCCS Policlinico San Matteo, Pavia, Italy.

G Amato (G)

UOC. Patologia Clinica, AO A. Cardarelli, Naples, Italy.

A Vella (A)

Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

L Pagano (L)

Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Università Cattolica del Sacro Cuore, Rome, Italy.

R Bandettini (R)

Clinical Pathology and Microbiology Laboratory Unit, Istituto Giannina Gaslini, Genoa, Italy.

G De Lorenzis (G)

Department of Agricultural and Environmental Sciences-Production, Landscape, Agroenergy, Università degli Studi di Milano, Milan, Italy.

M Cogliati (M)

Department of Biomedical Sciences for Health, Università degli Studi di Milano, Milan, Italy.

L Romanò (L)

Department of Biomedical Sciences for Health, Università degli Studi di Milano, Milan, Italy.

A Tortorano (A)

Department of Biomedical Sciences for Health, Università degli Studi di Milano, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH